Prelude Capital Management, LLC Exelixis, Inc. Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $229,028 - $267,199	11,260 New	11,260 $253,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $18,408 - $26,144	1,174 Added 11.15%	11,704 $184,000
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $183,643 - $243,874	10,530 New	10,530 $219,000
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $41,709 - $69,482	-2,534 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $36,641 - $55,241	2,534 New	2,534 $44,000
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $126,452 - $165,330	-6,680 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $86,396 - $109,142	4,408 Added 194.01%	6,680 $159,000
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $1,540 - $1,863	83 Added 3.79%	2,272 $49,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $44,255 - $63,716	-1,998 Reduced 47.72%	2,189 $48,000
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $55,341 - $70,644	2,284 Added 120.02%	4,187 $127,000
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $44,435 - $55,643	1,903	1,903 $46,000

564

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.